Post Hoc Analysis of Treatment Burden Reduction with AXPAXLI (also known as OTX-TKI)

August 3, 2026

OCULAR THERAPEUTIX

Retina experience redefined™

Forward Looking Statements and Disclaimers

Any statements in this presentation about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company's product candidates, including the design of, and the timing of the enrollment of the Company's SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI™ (also called OTX-TKI) for the treatment of wet AMD; the Company's plans to advance the development of AXPAXLI and its other product candidates, including in additional indications such as NPDR; the size of potential markets for the Company's product candidates; the potential utility or adoption, if approved, of any of the Company's product candidates; the sufficiency of the Company's cash resources; and other statements containing the words "anticipate", "believe", "estimate", "expect", "intend", "designed", "goal", "may", "might", "plan", "predict", "project", "target", "potential", "will", "would", "could", "should", "continue", and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing DEXTENZA® or any product or product candidate that receives regulatory approval; the ability to retain regulatory approval of DEXTENZA or any product or product candidate that receives regulatory approval; the initiation, design, timing, conduct, and outcomes of clinical trials, including the SOL-1 trial, the SOL-R trial, and the Company's other ongoing clinical trials; the risk that the U.S. Food and Drug Administration, or FDA, will not agree with the Company's interpretation of the written agreement under the SPA for the SOL-1 trial and the FDA's other written guidance for the SOL clinical program; the risk that even though the FDA has agreed with the overall design of the SOL clinical program, the FDA may not agree that the protocols and statistical analysis plans or the data generated by the SOL clinical program supports potential marketing approval, even if both SOL-1 and SOL-R are successful and meet their primary endpoints; the risk that the Company and the FDA may not agree on the registrational pathway for AXPAXLI for NPDR, DME or any other indication; uncertainty as to whether the data from earlier clinical trials will be predictive of the data of later clinical trials, particularly later clinical trials that have a different design or utilize a different formulation than the earlier trials, whether preliminary or interim data from a clinical trial or post-hoc analysis of clincal data will be predictive of final data from such trial, or whether data from a clinical trial assessing a product candidate for one indication will be predictive of results in other indications; the timing of availability of data from clinical trials and expectations regarding the timing and sufficiency of regulatory submissions and approvals; the Company's scientific approach and general development progress; the availability or commercial potential of the Company's product candidates; uncertainties inherent in estimating the Company's cash runway, future expenses, and other financial results, including its ability to fund future operations, including clinical trials; the Company's existing indebtedness and the ability of the Company's creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default; the Company's ability to enter into strategic alliances or generate additional funding on a timely basis, on favorable terms, or at all; and other factors discussed in the "Risk Factors" section contained in the Company's quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

This presentation contains references to the Company's trademarks and trade names and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this presentation may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable law, its rights or the rights of the applicable licensor to these trademarks and trade names. The Company does not intend its use or display of other companies' trademarks or trade names to imply a relationship with, or endorsement or sponsorship of it by, any other companies. AXPAXLI is a trade name which the Company uses to refer to its OTX-TKI product candidate. The FDA has not approved AXPAXLI or OTX-TKI as product names.

This presentation discusses investigational product candidates in development. Their efficacy and safety profiles have not been established, and they have not been approved for marketing by the FDA or any other regulatory agency.

Treatment Burden Reduction vs Aflibercept (2 mg) at ~1 year

	LOADING DOSES INCLUDED	LOADING DOSES NOT INCLUDED
VABYSMO[1] TENAYA/LUCERNE Phase 3	**14%** (6.4 vs 7.4)	**46%** (2.4 vs 4.4)
EYLEA HD[2] PULSAR Phase 3	**29%** (5.49 vs 7.7) (weighted average Q12 and Q16 arms)	**47%** (2.49 vs 4.7) (weighted average Q12 and Q16 arms)
4D-150[3] PRISM Phase 2b (3E10 dose)	**50%** (3.97 vs 8) vs projected on-label aflibercept (2 mg) control	**51%** (2.97 vs 6) vs projected on-label aflibercept (2 mg) control
ADVM-022[4] LUNA Phase 2b (2E11 dose)	**65%** (2.8 vs 8) vs projected on-label aflibercept (2 mg) control	**70%** (1.8 vs 6) vs projected on-label aflibercept (2 mg) control
ABBV-RGX-314[5] Subretinal Phase 1/2a (Cohorts 3/4)	**36 - 60%** (3.2/5.1 vs 8) vs projected on-label aflibercept (2 mg) control	**49 - 63%** (2.2/4.1 vs 6) vs projected on-label aflibercept (2 mg) control
AXPAXLI[6] SOL-1 Phase 3 using SOL-R rescue criteria of >5 letters & ≥75 µm from baseline	**56%** (3.95 vs 9) vs projected on-label aflibercept (2 mg) control	**72%** (1.95 vs 7) vs projected on-label aflibercept (2 mg) control

†AXPAXLI durability measured over 60 weeks to include loading doses at Week -8 and Week –4 others calculated over 48 to 52 weeks

OCULAR THERAPEUTIX Retina experience redefined™

OCUL Internal Post Hoc Analysis of Projected Treatment Burden Reductions in Respective Studies. Assumptions made in computing figures. Results intended to be illustrative as the analysis is subject to the limitations of cross-trial comparisons, including different enrollment and rescue criteria.

1. U.S. Food and Drug Administration. Vabysmo (Faricimab) Clinical Review – application number 761235. 2. U.S. Food and Drug Administration. Eylea HD (aflibercept 8mg) Summary Review – application number 761355. 3. Pieramici D, Phase 2b Population Extension Cohort Evaluating 4D-150 in Neovascular Age-Related Macular Degeneration: 52-Week Results, Presented at the Angiogenesis, Exudation and Degeneration 2025 Conference. 4. Wykoff C, Ixo-Vec Gene Therapy for nAMD: Clinical Progress from the LUNA Phase 2 Trial, Presented at the FLORetina 2025 Conference. 5. Ho A et al, Subretinal Delivery of RGX-314 for Neovascular AMD: End of Phase I/Iia Study Results, Presented at the Retina Society 2021 Annual Meeting. 6. Data on file, Ocular Therapeutix